PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

The Quick Take
– No dose-limiting toxicities observed across doses from 10 to 750 mg, with no PT0253-specific pre-treatment prophylaxis required – – Monotherapy antitumor activity observed in colorectal and pancreatic cancers, including a partial response in a patient previously treated with a...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
NBIM agrees to sell Zurich office complex for CHF850m
UBS Asset Management funds to take over long-term lease contract. CRE Herald Register for Free Access Create your free account to read this article and receive…
Business
Northern California contractor provides advice on El Niño preparation
Peter Levi Plumbing, Heating, Cooling and Drains urges homeowners to check three main plumbing functions in advance of flooding NOVATO, Calif., Nov. 20, 2026…
Business
La Arizona Veterans Research and Education Foundation y el YBI investigan el alzhéimer
-La Arizona Veterans Research and Education Foundation, en apoyo al Phoenix VA Health Care System, y el Young Blood Institute anuncian un acuerdo de…
Business
Pam Harrington Exclusives Surpasses $200 Million in Sales Through October, Marking Its Strongest Year In The Company's 48-Year History
With 111 closed transactions, five agents, and more than $43 million under contract, the independent, women-owned brokerage continues to demonstrate the value…
